Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.64 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.64 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.57 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18589522 | 0.81 | GABRA1 (0.76) | GABRA1GABRB2GABRB1GABRA3MEN1 | |
| SCHEMBL4169502 | 0.80 | LMNA (0.42) | GABRA1GABRB2MEN1ALDH1A1HPGD | |
| SCHEMBL22843745 | 0.80 | GABRA1 (0.83) | GABRA1GABRB2GABRB1GABRA3MEN1 | |
| SCHEMBL3982430 | 0.80 | LMNA (0.56) | MEN1ALDH1A1TP53HPGDKMT2A | |
| SCHEMBL4164845 | 0.79 | GABRA1 (0.55) | GABRA1GABRB2GABRB1GABRA3MEN1 | |
| SCHEMBL7291769 | 0.79 | GABRA1 (1.00) | GABRA1GABRB2GABRB1GABRA3MEN1 | |
| SCHEMBL4169399 | 0.79 | LMNA (0.41) | GABRA1GABRB2GABRB1GABRA3KMT2A | |
| SCHEMBL5255090 | 0.78 | LMNA (0.46) | MEN1ALDH1A1HPGDKMT2AHSD17B10 | |
| SCHEMBL4176943 | 0.78 | KMT2A (0.44) | GABRA1GABRB2MEN1ALDH1A1HPGD | |
| SCHEMBL4173128 | 0.77 | LMNA (0.48) | MEN1ALDH1A1HPGDKMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062218-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| US-20070293472-A1 | Novel 14 and 15 Membered Ring Compounds | GLAXO GROUP LIMITED (GB) | 2007-12-20 | — | — | US | disclosed |
| EP-1824871-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-29 | — | — | EP | disclosed |
| EP-1628989-B1 | NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS | GLAXO GROUP LTD (GB) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006050940-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293472-A1 | Novel 14 and 15 Membered Ring Compounds | IL17A, CYP51A1, IL15 | GABRA1 3222/4885GABRB2 3095/4885GABRB1 2870/4885 |
| US-20090062218-A1 | MACROLONE COMPOUNDS | CYP51A1, MRPL21, MYD88 | GABRA1 3341/4885GABRB2 4256/4885GABRB1 3850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.